Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19868487 | 0.83 | LPL (0.32) | LPLLIPG | |
| SCHEMBL16094973 | 0.81 | PSEN1 (0.34) | LPLLIPGTSHRTDP1L3MBTL1 | |
| SCHEMBL18696943 | 0.76 | P2RX7 (0.37) | LPLLIPGMAPK1 | |
| SCHEMBL17448814 | 0.76 | TSHR (0.31) | TSHRTDP1L3MBTL1ESR1ALDH1A1 | |
| SCHEMBL17449164 | 0.74 | LPL (0.32) | LPLLIPG | |
| SCHEMBL15185767 | 0.72 | P2RX7 (0.31) | LPLLIPGMAPK1 | |
| SCHEMBL16094883 | 0.70 | HSD11B1 (0.32) | ALDH1A1 | |
| SCHEMBL18925680 | 0.68 | LMNA (0.38) | TSHRL3MBTL1ALDH1A1LMNACYP1A2 | |
| SCHEMBL17178006 | 0.68 | P2RX7 (0.35) | MAPK1 | |
| SCHEMBL17177887 | 0.68 | P2RX7 (0.35) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | US | disclosed |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-20180346454-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-06 | — | — | US | disclosed |
| US-10071991-B2 | Substituted pyridine derivatives useful as c-fms kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-11 | — | — | US | disclosed |
| EP-3284742-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | Janssen Pharmaceutica NV (BE) | 2018-02-21 | — | — | EP | disclosed |
| EP-2970232-B1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-14 | — | — | EP | disclosed |
| US-20170158678-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-20170158678-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9611259-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-9611259-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-9611259-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-20160016942-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016942-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016942-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970232-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151258-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151258-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016942-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
| US-10071991-B2 | Substituted pyridine derivatives useful as c-fms kinase inhibitors | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
| US-20180346454-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
| US-20170158678-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885TSHR 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.